The troubles of RA treatment
Brian Kenney, who is a spokesman for Johnson and Johnson, stated how serious and complex that RA is. Kenney said that because patients are frequently forced to cycle through several different therapies before they find one that is effective in treating their disease that the benefit of sirukumab is worth the risk.
Glaxo Smith Kline Plc. was originally in a cooperative arrangement with Johnson and Johnson in developing sirukumab. Glaxo Smith Kline Plc. had sole rights to the medicine in North America, Central American, and South America, but states that they would end their participation in the program and return all of the rights back to Johnson and Johnson.